Published in Adv Drug Deliv Rev on April 25, 2017
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science (2000) 6.22
Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum (2001) 5.24
Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science (1998) 5.19
Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol (2004) 5.13
An overview of tissue and whole organ decellularization processes. Biomaterials (2011) 4.78
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol (2010) 3.44
Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol (1999) 3.42
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 3.32
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med (2007) 3.09
Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials (2009) 2.98
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater (2011) 2.71
The role of antibody concentration and avidity in antiviral protection. Science (1997) 2.45
Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther (2009) 2.44
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med (2016) 2.17
Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. Science (2016) 2.16
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2009) 2.03
Virus-like particles in vaccine development. Expert Rev Vaccines (2010) 2.02
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest (2000) 2.00
Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am (2003) 1.97
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation (2001) 1.90
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol (2012) 1.81
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials (2011) 1.67
Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc (2012) 1.57
Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A (2005) 1.57
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53
Tissue matrix arrays for high-throughput screening and systems analysis of cell function. Nat Methods (2015) 1.52
Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials (2009) 1.49
Glatiramer acetate: evidence for a dual mechanism of action. J Neurol (2008) 1.49
Macrophage participation in the degradation and remodeling of extracellular matrix scaffolds. Tissue Eng Part A (2009) 1.49
Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum (2007) 1.38
An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss. Sci Transl Med (2014) 1.38
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A (2009) 1.31
Host response to human acellular dermal matrix transplantation in a primate model of abdominal wall repair. Tissue Eng Part A (2008) 1.30
Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol (2003) 1.30
S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol (2011) 1.27
Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials (2012) 1.27
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties. Mol Pharm (2012) 1.22
Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep (2011) 1.20
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
Comparing the biological impact of glatiramer acetate with the biological impact of a generic. PLoS One (2014) 1.17
Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev (2015) 1.15
Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther (2004) 1.11
The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology (2010) 1.10
Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes--regulation by IFN-gamma and IL-4. J Immunol (1994) 1.09
Extracellular matrix as an inductive scaffold for functional tissue reconstruction. Transl Res (2013) 1.09
Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 1.09
Galalpha(1,3)Gal epitope in porcine small intestinal submucosa. Tissue Eng (2000) 1.08
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther (2006) 1.08
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Regulating MCP-1 diffusion in affinity hydrogels for enhancing immuno-isolation. J Control Release (2009) 1.04
Methods of tissue decellularization used for preparation of biologic scaffolds and in vivo relevance. Methods (2015) 1.02
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2004) 1.02
Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med (2009) 1.02
Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater (2012) 1.01
Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials (2013) 1.01
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics (2007) 1.01
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol (2004) 1.01
Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials (2012) 1.00
The effect of source animal age upon the in vivo remodeling characteristics of an extracellular matrix scaffold. Biomaterials (2012) 1.00
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol (2001) 0.99
Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection. J Control Release (2010) 0.99
Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials (2012) 0.99
Gradated assembly of multiple proteins into supramolecular nanomaterials. Nat Mater (2014) 0.99
The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials (2005) 0.99
Differential effects of agarose and poly(lactic-co-glycolic acid) on dendritic cell maturation. J Biomed Mater Res A (2006) 0.98
Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc Natl Acad Sci U S A (2004) 0.98
Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine (2011) 0.98
The effect of source animal age upon extracellular matrix scaffold properties. Biomaterials (2010) 0.97
Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol (2016) 0.95
Macrophage functional polarization (M1/M2) in response to varying fiber and pore dimensions of electrospun scaffolds. Biomaterials (2013) 0.95
New players driving inflammation in monogenic autoinflammatory diseases. Nat Rev Rheumatol (2014) 0.95
The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials (2013) 0.94
Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold spring harb symp quant biol. 1989. 54: 1-13. J Immunol (2013) 0.94
Damage associated molecular patterns within xenogeneic biologic scaffolds and their effects on host remodeling. Biomaterials (2011) 0.94
Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response. ACS Nano (2015) 0.93
Molecular aspects of microparticle phagocytosis by dendritic cells. J Biomater Sci Polym Ed (2006) 0.93
Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). J Neurol Sci (2015) 0.92
The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev (2012) 0.92
Macrophage polarization in response to ECM coated polypropylene mesh. Biomaterials (2014) 0.92
Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. Eur Cell Mater (2015) 0.92
Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol (2007) 0.91
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler (2003) 0.90
Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Res (2002) 0.90
The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials (2014) 0.90